MDGL

Madrigal Pharmaceuticals Inc

$85.57

+0.15 (+0.18%)

chg neg

quotes and stock data may be delayed 15 minutes

52 wk low

83.71

52 wk hi

142.62

Cash

$307.2M

Burn Rate (Qtr)

$53.0M

Mkt Cap

$1.4b

Avg Volume

139,824

*cash/burn updated:

Q1 '21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We have found any drug for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Loading Catalysts...

search in progress

Pipeline powered by

MDGL

BPIQ_Logo_RGB-01.jpg

Company Profile

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy.

Recent Posts

See what the community is saying - click to see full post.